Cargando…

MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells

Glioblastoma (GBM) contains stem‐like cells (GSCs) known to be resistant to ionizing radiation and thus responsible for therapeutic failure and rapidly lethal tumor recurrence. It is known that GSC radioresistance relies on efficient activation of the DNA damage response, but the mechanisms linking...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bacco, Francesca, D'Ambrosio, Antonio, Casanova, Elena, Orzan, Francesca, Neggia, Roberta, Albano, Raffaella, Verginelli, Federica, Cominelli, Manuela, Poliani, Pietro L, Luraghi, Paolo, Reato, Gigliola, Pellegatta, Serena, Finocchiaro, Gaetano, Perera, Timothy, Garibaldi, Elisabetta, Gabriele, Pietro, Comoglio, Paolo M, Boccaccio, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130292/ https://www.ncbi.nlm.nih.gov/pubmed/27138567 http://dx.doi.org/10.15252/emmm.201505890

Ejemplares similares

MicroRNA 483‐3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis
por: Candiello, Ermes, et al.
Publicado: (2023)

Protocol for in vitro establishment of heterogeneous stem-like cultures derived from whole human glioblastoma tumors
por: De Bacco, Francesca, et al.
Publicado: (2023)

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth
por: Luraghi, Paolo, et al.
Publicado: (2012)

Activation of the MET receptor attenuates doxorubicin‐induced cardiotoxicity in vivo and in vitro
por: Gallo, Simona, et al.
Publicado: (2020)

FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration
por: Frattini, Véronique, et al.
Publicado: (2012)

EBF1 is expressed in pericytes and contributes to pericyte cell commitment
por: Pagani, Francesca, et al.
Publicado: (2021)

Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
por: Orzan, Francesca, et al.
Publicado: (2023)

Leptomeningeal dissemination of anaplastic medullary cone astrocytoma: an unexpected findings in a patient with leptomeningeal enhancement and clinical history of multiple myeloma
por: Daffini, Linda, et al.
Publicado: (2021)

MET∆14 promotes a ligand-dependent, AKT-driven invasive growth
por: Cerqua, Marina, et al.
Publicado: (2022)

Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy
por: Gallo, S, et al.
Publicado: (2014)

ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference
por: De Bacco, Francesca, et al.
Publicado: (2021)

An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023)

HGF and MET: From Brain Development to Neurological Disorders
por: Desole, Claudia, et al.
Publicado: (2021)

Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing
por: Liserre, Roberto, et al.
Publicado: (2023)

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
por: Verginelli, Federica, et al.
Publicado: (2021)

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
por: Martin, Valentina, et al.
Publicado: (2019)

MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor
por: Gallo, Simona, et al.
Publicado: (2022)

An mTOR feedback loop mediates the ‘flare’ (‘rebound’) response to MET tyrosine kinase inhibition
por: Altintas, D. M., et al.
Publicado: (2023)

The Met oncogene and basal-like breast cancer: another culprit to watch out for?
por: Gastaldi, Stefania, et al.
Publicado: (2010)

The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3
por: Gallo, Simona, et al.
Publicado: (2020)

The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor
por: Altintas, Dogus Murat, et al.
Publicado: (2022)

ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
por: Lazzari, Luca, et al.
Publicado: (2013)

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met
por: Basilico, Cristina, et al.
Publicado: (2008)

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
por: Virzì, Anna Rita, et al.
Publicado: (2018)

Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line
por: Pagani, Francesca, et al.
Publicado: (2023)

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin
por: Stella, Giulia M., et al.
Publicado: (2017)

Lactotroph PitNET/adenoma associated to granulomatous hypophysitis in a patient with Crohn's disease: A case report
por: Pietrantoni, Alberto, et al.
Publicado: (2022)

A receptor-antibody hybrid hampering MET-driven metastatic spread
por: Modica, Chiara, et al.
Publicado: (2021)

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
por: Modica, Chiara, et al.
Publicado: (2018)

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

Treatment with anti-FcεRIα antibody exacerbates EAE and T-cell immunity against myelin
por: Musio, Silvia, et al.
Publicado: (2017)

Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

A Natural Hepatocyte Growth Factor/Scatter Factor Autocrine Loop in Myoblast Cells and the Effect of the Constitutive Met Kinase Activation on Myogenic Differentiation
por: Anastasi, Sergio, et al.
Publicado: (1997)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
por: Chiriaco, Cristina, et al.
Publicado: (2022)

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody
por: Modica, Chiara, et al.
Publicado: (2020)

Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
por: Pisacane, Alberto, et al.
Publicado: (2022)

Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
por: Pisacane, Alberto, et al.
Publicado: (2022)

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells
por: D'Amico, Lucia, et al.
Publicado: (2016)

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uehq65f59ghm55rmtqemuc5601